Anaptysbio (ANAB) Accumulated Expenses (2016 - 2026)

Anaptysbio has reported Accumulated Expenses for 11 years, with the latest figure at $5.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 84.61% year-over-year to $5.5 million; the trailing twelve-month figure through Mar 2026 stood at $5.5 million (down 84.61% YoY), and the FY2025 full-year result was $11.1 million, up 31.31% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $5.5 million, down from $11.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $38.4 million in Q3 2024, with the low at $5.5 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $24.8 million across 5 years, with a median of $30.2 million in 2025.
• Annual changes were most pronounced in 2023 — Accumulated Expenses surged 110.39% — and 2026, when it sank 84.61%.
• Anaptysbio's Accumulated Expenses stood at $21.6 million in 2022, then jumped by 43.15% to $31.0 million in 2023, then plunged by 72.72% to $8.4 million in 2024, then soared by 31.31% to $11.1 million in 2025, then sank by 50.12% to $5.5 million in 2026.
• The last three Accumulated Expenses figures came in at $5.5 million (Q1 2026), $11.1 million (Q4 2025), and $33.2 million (Q3 2025), per Business Quant data.